Myeloablative Allogeneic Stem Cell Transplantation
Allogeneic Haemopoietic Stem Cell Transplantation Using Non Myeloablative Conditioning A Local Experience
... Allogeneic Haemopoietic Stem Cell Transplantation Using Non Myeloablative Conditioning A Local Experience ORIGINAL ARTICLE Allogeneic Haemopoietic Stem Cell Transplantation Using Non Myeloablative Con[.] ...
7
Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-cell Interaction
... and myeloablative (MA) conditioning (D), the presence of HLA class II-expressing cells and T-cells at the time of allogeneic stem cell transplantation (alloSCT) resembled the situation ...
10
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
... donor stem cells (250 stem cells per ...donor stem cells likely masked the beneficial effects of CXCR4 blockade on stem cell en- graftment and ...CD34 cell dose or ideal body ...
10
Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
... hematopoietic stem cell transplantation (allo-HSCT) is a curative approach for hematological malignancies ...standard myeloablative (MA) regimen consisting of total body irradiation ...
12
Hematopoietic stem cell transplantation for the management of follicular lymphoma
... FL. Allogeneic transplants should be offered to patients who are young, have a matched donor, and are beyond first ...CR. Myeloablative regimens are associated with significant ...offer allogeneic ...
12
Clinical Significance of Pulmonary Function Tests in Long Term Survivors after Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
... 5; <40% = 6. LFS = FEV1 score + DLCO score. At the time of transplantation, patients were divided into stan- dard-risk and high-risk groups. Standard-risk patients included those with acute leukemia in complete ...
7
Individualized therapeutics in allogeneic stem cell transplantation
... and myeloablative drugs with the goal to cause suppression of the host immune system to prevent rejection, create ‘space’ in the bone marrow of the recipient to allow donor cell engraftment, and, if ...
201
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
... working party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Eligibility criteria included age ≥50 years, de novo AML in any disease status at SCT, transplants from HLA-compatible ...
10
Allogeneic hematopoietic stem cell transplantation: transfusion issues
... fatal. Allogeneic hematopoietic stem cell transplantation (AHSCT) is an intention-to-cure treatment strategy in several malignancies and nonmalignan- ...pre-transplantation ...
14
Microbiome mediation of infections in the cancer setting
... undergoing allogeneic HSCT (allo-HSCT), a cancer treatment that simultaneously exposes patients to cytotoxic chemotherapy, total body irradiation, immuno- suppressants, and broad-spectrum ...after stem ...
7
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study
... Background: Allogeneic stem cell transplantation is the only curative option for patients with acute myeloid leukemia (AML) experiencing ...frequently myeloablative for patients ...
8
Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
... a myeloablative or nonmyeloablative allogeneic HSCT at the Hematopoietic Stem Cell Transplantation Unit of the University of Campinas Teaching Hospital, with related or not related HLA ...
8
<p>Identification and Treatment of Tuberculosis in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Review of the Literature</p>
... hematopoietic stem cell transplantation for thalassemia major among 330 recipients between January 2012 and August ...hematopoietic stem cell transplantation, regardless of the ...
8
Role of autologous and allogeneic stem cell transplantation in myeloma.
... intensity allogeneic transplant regimens can result in reliable donor engraftment with a relatively low mortality compared to high dose ...intensity allogeneic strategy can result in CR in over 50% of ...
24
Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms
... Stem cell therapy presents an intriguing alternative approach to treat epilepsy that is fundamentally different from anticon- vulsants and electrical stimulation which seek to manage the symptoms and not ...
12
<p>Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease</p>
... In our study, Dec-containing conditioning regimen was found to protect against grade II to IV aGvHD and relapse. Previous studies have demonstrated that the addition of Decitabine may contribute to better aGVHD control ...
9
PCR in Diagnosis of Invasive Aspergillosis: a Meta Analysis of Diagnostic Performance
... sequential cell lysis methods could not improve PCR assay performance for patients with IA, in contrast to what would be expected for samples spiked with Aspergillus ...
12
Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families
... T cell receptor (TCR) Vβ CDR3-size and sequence is being used to characterize alloreactive versus tumor-specific T- cell ...T cell subfamilies might be positively se- lected from the donor inoculum ...
12
Allogeneic Hematopoietic Stem-Cell Transplantation for Leukocyte Adhesion Deficiency
... marrow transplantation; Bu, busulphan; Cam1G, Campath 1G; Cam1H, Campath 1H; CY, cyclophosphamide; CyA, cyclosporin; Flu Mel, Fludarabine, Melphalan; Flu Treo, Fludarabine, Treosulphan; HAPL, haploidentical donor ...
7
Mantle cell lymphoma and its management: where are we now?
... MCL comprises of 2.5–6% of NHLs [9, 10]. MCL usu- ally have either nodular or diffuse pattern of growth. Approximately 20% MCL cases show blastoid morphol- ogy. The MCL cells express surface immunoglobulins, including Ig ...
9